Calquence – Display Banners Conference – 23464
ASCO A Focus On Leukemia eBook
ASCO Leukemia 2022.indd
Read More
High Mortality Risk in Patients With Leukemia Hospitalized With CDI
Among patients with leukemia admitted to the hospital with Clostridioides difficile infection...
Read More
Various Racial Disparities in Patients With TP53m Acute Myeloid Leukemia
Black/Hispanic patients with TP53 mutation (m) acute myeloid leukemia (AML) had worse overall...
Read MoreVarious Racial Disparities in Patients With TP53m Acute Myeloid Leukemia
Black/Hispanic patients with TP53 mutation (m) acute myeloid leukemia (AML) had worse overall survival (OS) compared with White patients, according to study results presented by Talha Badar, MBBS, MD, at the 2022 American...
Read More
Acalabrutinib Still Outperforming in R/R CLL: Three-years Follow-up of ASCEND
A presentation at the American Society of Clinical Oncology (ASCO) 2022 Annual meeting, which was...
Read More
OS benefit seen in 5-year data on ELEVATE-TN trial in CLL
A presentation at the American Society of Clinical Oncology (ASCO) 2022 Annual meeting, which was...
Read MoreASCO Voices Event
This year ASCO Voices will be held on Saturday, June 4, from 12:00 PM – 1:00 PM CDT, at the Arie Crown Theater in McCormick Place Here are this year’s ASCO Voices: Cancer: Common Humanity, Different Worlds Kevin...
Read MoreContinuing Education At ASCO 2022
Sessions at the 2022 ASCO Annual Meeting offer Continuing Medical Education (CME) credits and ABIM and ABP Maintenance of Certification (MOC) points for physicians. Nursing and pharmacy CE credits will not be provided this year,...
Read MoreWhy To Attend ASCO 2022
Join more than 40,000 oncology professionals from around the world at the 2022 ASCO Annual Meeting. Stay up to date on new clinical cancer advances in every area of cancer research, gain real-time insights from world-renown...
Read More
CLL: Acalabrutinib ± Obinutuzumab Vs Obinutuzumab + Chlorambucil
Researchers previously demonstrated improved efficacy of acalabrutinib (A) obinutuzumab (O) vs. O...
Read More
R/R CLL: Acalabrutinib Vs Rituximab With Idelalisib or Bendamustine
Acalabrutinib (Acala) was a next-generation, highly selective, covalent Bruton tyrosine kinase...
Read More
SEER Program Data: Chronic Lymphocytic Leukemia Patients
Over the last 2 decades, treatment for chronic lymphocytic leukemia (CLL) has evolved...
Read More
Survival Outcomes in Chronic Lymphocytic Leukemia Patients
For a study, researchers sought to see if patients with chronic lymphocytic leukemia (CLL) who...
Read MoreChronic Lymphocytic Leukemia Treated at Academic Centers
For a study, researchers sought to see if patients with chronic lymphocytic leukemia (CLL) who were treated at Commission on Cancer accredited academic centers (ACs), which had a high clinical volume, access to clinical trials,...
Read More
Leukemia Mortality Trends in the United States, 1999-2018
Leukemia was the seventh most prevalent cause of mortality among cancer patients. It was...
Read More
Psychological Mobile App for Acute Myeloid Leukemia (AML) Patients
During their hospitalization for rigorous chemotherapy, patients with Acute Myeloid Leukemia (AML)...
Read More